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Sonic Hedgehog (Shh/GLI) and EGFR signaling pathways modulate Neural Stem Cell
(NSC) proliferation. How these signals cooperate is therefore critical for understanding
normal brain development and function. Here we report a novel acute effect of Shh
signaling on EGFR function. We show that during late neocortex development, Shh
mediates the activation of the ERK1/2 signaling pathway in Radial Glial cells (RGC)
through EGFR transactivation. This process is dependent on metalloprotease activity and
accounts for almost 50% of the EGFR-dependent mitogenic response of late NSCs.
Furthermore, in HeLa cancer cells, a well-known model for studying the EGFR receptor
function, Shh also induces cell proliferation involving EGFR activation, as reflected by
EGFR internalization and ERK1/2 phosphorylation. These findings may have important
implications for understanding the mechanisms that regulate NSC proliferation during
neurogenesis and may lead to novel approaches to the treatment of tumors.
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INTRODUCTION
Themammalian neocortex develops from neural stem/progenitor
cells (NSCs) that generate neurons, astrocytes and oligodendro-
cytes under the control of a complex array of environmental
factors (Caviness et al., 1995). The maintenance of these cells
plays a crucial role in normal brain development and home-
ostasis, and its misbehavior has been related to the origin of
tumors (McCarthy, 2012). Among the molecules that regulate
NSC proliferation and maintenance, Sonic Hedgehog (Shh) has
been addressed as an important mitogenic factor that regulates
NSC proliferation, both in the embryonic and adult brain, act-
ing together with the Epidermal Growth Factor (EGF) (Caric
et al., 2001; Palma and Ruiz i Altaba, 2004; Palma et al.,
2005). Shh and EGF synergic action is necessary to induce
late NSC proliferation and cross talk between the Shh and
EGF signaling pathways has been reported based on canonical
Shh/Gli activity and modulation of EGFR expression (Palma
and Ruiz i Altaba, 2004; Bigelow et al., 2005; Palma et al.,
2005; Ruiz i Altaba et al., 2007). Importantly, recent evidence
has also involved Shh/Gli and EGFR cooperative interaction in
oncogenic transformation (Schnidar et al., 2009). Therefore, a
Abbreviations: NSC, neural stem cells; nsps, neurospheres; Shh, Sonic Hedgehog;
CNS, Central Nervous System; Cyc, cyclopamine; Pur, purmorphamine.
detailed understanding of the downstream processes and molec-
ular players involved in this cooperative growth factor interaction
are important not only for brain development but also for the
identification of novel drug targets and rational-based combina-
tion therapies (Mimeault and Batra, 2010; Mangelberger et al.,
2012).
Canonical Hedgehog signaling involves the binding of Shh
to its receptor, Patched1 (Ptch1), relieving a repression of Ptch1
upon the co-receptor Smoothened (Smo), which is a GPCR
presumably coupled to an inhibitory G-protein (Gαi) (Ogden
et al., 2008; Lappano and Maggiolini, 2011). Activation of Smo
decreases the production of cAMP via Gαi, thus PKA is inhib-
ited and no longer phosphorylates the Gli transcription factors,
the only well-known mediators of Shh, ultimately leading to their
stabilization and activation (Huangfu and Anderson, 2006).
The EGF receptor of the tyrosine-kinase ERbB family
(ERbB1-4) is one of the most widely distributed control systems
of cell proliferation and differentiation, not only by responding to
its own ligands but also serving as a nodal element for a variety
of other stimuli (Carpenter, 1999; Yarden and Sliwkowski, 2001).
Upon ligand binding, the receptor dimerizes and its intracellular
tyrosine kinase domain becomes activated leading to phosphory-
lation of the receptor itself and several intracellular proteins with
signaling or vesicular trafficking functions (Schlessinger, 2000;
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Sorkin and Goh, 2008). Activated EGFR, as other tyrosine-kinase
receptors, signals via the Ras/Raf/MEK/MAPK, STAT, PI3K/AKT,
and PLC-γ pathways and changes its broadcasting location dur-
ing endocytosis and recycling, remaining active during vari-
able periods of intracellular trafficking before entering the
lysosomal-degradation route that finally ends its signaling activ-
ity (Schlessinger, 2000; Piper and Luzio, 2007; Sorkin and Goh,
2008).
It is well-known that besides its own stimulus, the EGFR can
also be indirectly transactivated by signals emerging from a vari-
ety of other receptors, most notably by GPCRs coupled to Gαi
or Gαq (Daub et al., 1996; Carpenter, 1999; Gschwind et al.,
2001; Buvinic et al., 2007). Transactivation usually involves met-
alloprotease (MMPs)-mediated release of soluble EGFR ligands
by cleavage of transmembrane ligand precursors at the cell sur-
face (Izumi et al., 1998; Prenzel et al., 1999). Transactivation of
EGFR has not been explored during late central nervous system
(CNS) embryogenesis. It remains unknown whether EGFR func-
tion in NSCs is controlled by Shh via transactivation as recently
described in embryonic stem cells (Heo et al., 2007). Here we
studied the acute effect of Shh signaling over EGFR function in
NSCs during late brain development. These cells are biologically
characterized by the in vitro double requirement for Shh and
EGF for cell proliferation. We show for the first time that Shh
is capable of modulating EGFR-dependent proliferation of late
cortex NSCs through EGFR mediated transactivation and endo-
cytosis. We identified a subpopulation of NSCs constituted by
Radial Glial Cells (RGC) as the main target of Shh. Moreover, we
extended our results providing evidence that Shh also induced
EGFR to mitogenic signaling, and to become endocytosed but
not degraded, in HeLa cells, a well-characterized cancerous cell
model for the study of EGFR function (Salazar and González,
2002; Buvinic et al., 2007; Sigismund et al., 2008; Norambuena
et al., 2009). Thus, Shh can modulate EGFR signaling in different
cell contexts. Such kind of control likely contributes to regulate
the function of stem and progenitor cells during brain develop-
ment and also the pathogenic arising and progression of several
cancers.
MATERIALS AND METHODS
REAGENTS AND ANTIBODIES
Cyclopamine (Infinity Pharmaceuticals, Inc.), recombinant
octyl-modified Shh-N protein (R&D Systems), Purmorphamine
(Calbiochem), EGF (human recombinant, Invitrogen),
Tyrphostin (Calbiochem), Shh specific blocking antibody (5E-1),
Shh-N plus the Gli inhibitor Gant61 (ALEXIS). Anti-phospho
ERK, anti-total ERK, anti-β-actin and anti-β-tubulin, rabbit
anti-GFAP, PD98059 were all from Sigma. Sheep anti-EGFR
(Upstate), guinea pig polyclonal anti-GLAST, rabbit anti-Sox2,
Ilomastat were from Chemicon, mouse anti-PKCλ (Transduction
Labs), rabbit anti-caspase3 (Cell Signaling), polyclonal antibody
EGFR984 (Biosonda Biotechnology), monoclonal antibody
HB8506 (American Type Culture Collection), anti-phospho-
tyrosine 4G10 monoclonal antibody (gift kindly provided by
Dr. Maria Rosa Bono, Universidad de Chile, Santiago, Chile).
Fluorescent secondary antibodies used were anti-rabbit Alexa488
and anti-mouse Alexa555 (Invitrogen).
HeLa CELL CULTURE AND TREATMENTS
An in-house population of HeLa cells previously character-
ized for EGFR internalization and transmodulation (Salazar and
González, 2002; Buvinic et al., 2007; Norambuena et al., 2009)
were cultured in DMEM supplemented with 10% FBS and antibi-
otics (100U/ml penicillin and 100μg/ml streptomycin), main-
tained at 37◦C in a humidified atmosphere (95% air, 5% CO2).
HeLa cells permanently expressing EGFR-GFP were obtained by
transfection with pEGFP-N1-EGFR plasmid (kindly provided by
Dr. Alexander Sorkin, University or Pittsburgh, USA) using the
Lipofectamine 2000 method (Invitrogen). Selection was made in
1mg/ml geneticin sulfate (G418) to obtain stable transfectants
and the cells were then maintained in 0.8mg/ml G418. Before
the experiments, the cells were cultured to ∼80% confluence and
serum-starved for 24 h in media supplemented with 0.3% fetal
bovine serum (FBS), unless otherwise indicated. Treatments were
performed at 3.3μg/ml recombinant Shh, hedgehog inhibitor
Cyclopamine (Cyc) at 10μM, Shh specific blocking antibody
(5E-1) at 5mg/ml, Gli inhibitor Gant61 at 10μM, Hedgehog
agonist Purmorphamine (Pur) at 10μM and EGF at 1 and
50 ng/ml.
HeLa CELL RT-PCR AND IMMUNOBLOT
HeLa RNA preparation and RT-PCR specific reaction con-
ditions and sequences for the human hprt,ptc1, and gli1
primer pairs were as described (Palma and Ruiz i Altaba,
2004). For HeLa cells immunoblot assays, 60mg protein
from total cell extracts prepared as described (Salazar and
González, 2002) were resolved on 10% polyacrylamide SDS
gels and transferred onto nitrocellulose (Schleicher and Schuell,
Germany). When required, EGFR was immunoprecipitated
with the monoclonal antibody HB8506 and resolved by SDS-
PAGE and immunoblotted with anti-ubiquitin P4D1 antibody,
as described (Salazar and González, 2002). For total EGFR
detection, membranes were stripped and incubated with the
polyclonal antibody EGFR984 (Salazar and González, 2002).
Immunoblots were revealed with ECL (Amersham Biosciences)
and the bands were digitalized in a VISTA-T630 UMax scan-
ner driven by Adobe Photoshop CS (Adobe Systems, Mountain
View, CA).
HeLa CELL IMMUNOFLUORESCENCE AND BrdU ASSAY
To analyze EGFR internalization, HeLa EGFR-GFP stable cell
clones were grown on glass coverslips, treated and fixed for
30min at room temperature with 4% paraformaldehyde in PBS
supplemented with 0.1mM CaCl2 and 1mM MgCl2 (PBS-
CM). For BrdU incorporation assays, cells were grown in
cover slips to ∼50% confluence and serum-starved for 24 h
in media supplemented with 0.3% FBS. Cells were treated
with 3mM of BrdU and BrdU detection was performed as
previously described (Palma and Ruiz i Altaba, 2004) and
marker-positive cells were assessed as percentage of DAPI-
positive cells (5 random areas per experiment). All digital
fluorescence images were acquired at the time indicated on
a Zeiss Axiophot microscope with a Plan-APOCHROMAT
63X/1.4 oil immersion objective and the 14-bit Zeiss Axiocam
camera.
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NEOCORTICAL EXPLANTS AND PRIMARY NEUROSPHERE CULTURE
AND TREATMENTS
E18.5 cortical explants and Neurospheres (nsps) were obtained
from outbred strains BalbC and C57/BL6 mice, respectively,
and used for proliferation and differentiation and as described
(Reynolds and Weiss, 1996; Dahmane et al., 2001), nsps for no
more than three passages. Shh-N protein was used at 3.3μg/ml.
Other treatments included hedgehog inhibitor Cyclopamine
(Cyc) at 10μM, Hedgehog agonist Purmorphamine (Pur) at
10μM and EGF 1 and 10 ng/ml. For acute stimulation of nsps
Shh only was used. For proliferation assays nsps were plated on
coated coverslips and cultured for 48 h in 10 ng/ml of EGF in the
presence of Cyc or 1 ng/ml of EGF plus Shh (Palma and Ruiz i
Altaba, 2004). To evaluate a possible role for the Shh pathway in
RG cell maintenance nsps were deprived of EFG and cultured in
the presence or absence of Shh alone to permit cell differentia-
tion for 7 days, exchanging media every 3 days. Pharmacological
inhibition with Cyc was performed similarly.
All animal procedures were in accordance with the Chilean leg-
islation and were approved by Institutional Animal Care and Use
Committees.
NEUROSPHERE BrdU INCORPORATION AND IMMUNOFLUORESCENCE
Incorporation of BrdU (3mM, 2 h prior to culture fixation) and
immunofluorescence detection on NSCs was performed as pre-
viously described (Dahmane et al., 2001) and marker-positive
cells were assessed as percentage of DAPI-positive cells (5 random
areas per experiment, from at least three independent experi-
ments). Cells undergoing apoptosis were identified by caspase-3
immunodetection.
NEUROSPHERE IMMUNOBLOT AND IMMUNOPRECIPITATION
For immunoblot and immunoprecipitation, extracts of nsps or
explants were prepared in lysis buffer (10mM Tris-Hcl, 5mM
EDTA, 150mM NaCl buffer and 1% Triton X-100) containing
proteases and phosphatase inhibitors as described (Salazar and
González, 2002). Proteins in immunoblots were visualized by
ECL (Pierce) using horseradish peroxidase-conjugated secondary
antibodies (Jackson Immuno Research).
FLOW CYTOMETRY ON NEOCORTICAL EXPLANTS
Single cells dissociated from E18.5 neocortical explants prepared
following protocol described in (Dahmane et al., 2001) were fixed
in 2% paraformaldehyde for 15min, permeabilized with 0.05%
saponin and incubated for 30min on ice in 1% PBS-BSA with
anti-GFAP or anti-EGFR followed by secondary FITC-conjugated
antibodies were analyzed in a flow cytometer (FACSort; BD
Pharmingen) with CellQuest software. Statistical analysis.
Results were analyzed using Student’s t-test and One-Way
ANOVA. Values were expressed as mean ± the standard error of
the mean (SEM). Significance was set as p < 0.05.
RESULTS
Shh and EGF synergic action has recently been involved in cell
proliferation in embryonic stem cells (ES), and can occur via
Shh induced EGFR transactivation (Heo et al., 2007), thus ris-
ing the question of how extensive this control system might be
to other progenitor cell types or to other kind of cells, includ-
ing cancerous cells. EGFR can be transactivated by a variety of
stimuli. Depending on the kind and concentration of the ligand
(e.g., EGF or TGF-a), the activated EGFR displays variations in
signaling and cellular responses (Alwan et al., 2003; Sigismund
et al., 2008; Madshus and Stang, 2009; Roepstorff et al., 2009). It
is therefore important to analyze the contribution of Shh to the
modulation of EGFR function according to cell type and context.
Shh MEDIATES NSC PROLIFERATION TROUGH EGFR
MODULATION
During development, NSCs exhibit different requirements for
growth factors. This is reflected in the growth of nsps, which
require basic fibroblast growth factor (bFGF) at earlier embry-
onic stages and both Shh and EGF at late stages (Palma and Ruiz
i Altaba, 2004). Considering that EGFR-mediated proliferation
of cortical NSCs specifically requires EGF and Shh during late
brain development, we first examined the effect of the specific
inhibitors, Cyc (Hedgehog antagonist) and tyrphostin (EGFR
inhibitor, AG1478) (Ward et al., 1994; Chen et al., 2002), on cell
proliferation of E18.5 EGF-responsive nsps. Dissociated nsps were
plated on substrate-coated dishes and grown in the presence of
EGF (10 ng/ml) for 48 h. The cells were deprived of any growth
factor for 2 h to cause cell growth arrest and maximal exposal of
the EGFR to the cell surface, and were then stimulated with EGF
for 2 h in the absence or presence of Cyc or AG1478, added 30min
before ligand addition. EGF-induced cell proliferation, mea-
sured by BrdU incorporation, was reduced by 70% with AG1478
(100 nM) and 50% with Cyc (10μM) treatment, in agreement
with previous reports confirming basal Shh activity (Dahmane
et al., 2001; Palma and Ruiz i Altaba, 2004). Interestingly, simul-
taneous treatment with AG1478 and Cyc almost completely
abrogated cell proliferation (about 96%) (Figure 1A), without
significantly affecting apoptosis (Figure 1B). These results cor-
roborate that the EGFR and Shh signaling pathways collaborate
in the regulation of NSC proliferation during late embryogenesis.
Interestingly, these observations also suggest that besides regulat-
ing the level of EGFR expression, Shh substantially contributes to
the mitogenic response elicited by EGF signaling.
NSC PROLIFERATION INDUCED BY Shh REQUIRES EGFR
TRANSACTIVATION
The collaborative action of EGF and Shh can be exerted by the
activation of independent signaling pathways that might con-
verge upon yet unknown downstream elements. Alternatively,
the EGFR might constitute an upstream element shared by
both EGF and Shh. An obvious possibility is that Shh acutely
transactivates the EGFR and as a consequence activates the
Ras/Raf/MEK/ERK1/2 pathway involved in cell proliferation
(Traverse et al., 1994; Seger and Krebs, 1995). We first studied
the effects of Shh treatment over EGFR tyrosine-phosphorylation.
Strikingly, the EGFR immunoprecipitated from nsps treated with
Shh (3μg/ml) for 15min showed an increased phosphotyro-
sine content in immunoblots, which was abrogated by AG1478
(Figure 1C), thus reflecting EGFR activation. This Shh-induced
EGFR activation led to ERK1/2 activation, detectable within
15min and reaching a maximum by 30min (Figure 1D), which
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FIGURE 1 | Shh stimulation transactivates the EGFR leading to
mitogenic signaling via the ERK1/2 pathway. (A) EGF-dependent NSC
proliferation requires the Shh signaling pathway. Quantification of the
percentage of BrdU+ cells. The mitogenic activity decreased significantly
with either cyc (50%; ∗p < 0.03) or AG1478 (70%; ∗∗p < 0.01) and was
almost completely abrogated with both inhibitors (90%; ∗∗∗p < 0.001).
(B) Cells were treated with EGF (10 ng/ml), in the presence of either Cyc
(10μM), AG1478 (100 nM) or both drugs. Cells were fixed and cell death
was evaluated by positive caspase-3 labeling. The histogram shows that
treatment with inhibitors does not significantly change the percentage of
caspase-3-activated cells. Data represent the results of three independent
experiments. (C) Transactivation of the EGFR by Shh. Shh (3μg/ml) induced
an increment in the phospho-tyrosine activity of the EGFR, which was
abolished by AG1478 (100 nM), added 30min before. Tyrosine
phosphorylation of EGFR was detected by immunoblot after
immunoprecipitation. (D,E) Shh induces EGFR-dependent ERK1/2
activation. Nsps treated with Shh for the indicated time periods show
increased phospho-ERK, detected by immunoblot, maximal at 30min.
Independent experiments show that such ERK1/2 activation measured after
15min of Shh treatment is not only inhibited by Cyc (10μM), but also by
AG1478 (100 nM) (∗p < 0.03). (F) Shh treatment in NSCs induces EGFR
internalization. An adherent culture of nsps treated with 3.3μg/ml Shh for
30min shows EGFR internalization. EGF 50 ng/ml treatment was used as
positive control. (G) MEK inhibitor PD98059 added 30min before the
stimulus inhibits Shh mediated ERK activation. (∗p < 0.03).
(H) Immunofluorescence for BrdU shows that ERK1/2 signaling and
metalloprotease activity mediate Shh-dependent NSC proliferation.
Quantification of the percentage of BrdU+ cells stimulated with Shh show
a decreased proliferation of 60% by both PD98059 (100μM) and the
metalloprotease inhibitor Ilomastat (20μM), added 30min before
stimulation. Data represent mean ± SEM of 3 independent experiments in
triplicate (∗∗p < 0.01). Bar = 10μm (F) and Bar = 20μm (H).
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was also abrogated by Cyc and AG1478 (Figure 1E). These results
reveals for the first time that Shh transactivates the EGFR and its
downstream Ras/Raf/MEK/ERK1/2 signaling pathway in cortical
NSCs.
Because endocytosis plays a predominant role in EGFR func-
tion (Sorkin and Goh, 2008), and the intracellular trafficking and
signaling consequences depend on the intensity of ligand-induced
stimulation (Sigismund et al., 2008), we asked whether the trans-
activation elicited by Shhmight led to receptor internalization. To
answer this question we dissociated and plated nsps on substrate-
coated dishes so as to obtain monolayers of cells that can be easily
analyzed for EGFR endocytosis by indirect immunofluorescence.
The cells were grown in the presence of EGF (10 ng/ml) for 48 h
and depleted for 2 h before the experiments to induce maximal
exposure of the EGFR to the cell surface. Treatment with Shh
(3.3μg/ml) induced a redistribution of EGFR from the cell sur-
face to juxtanuclear endosomal compartments, although of less
magnitude compared with EGF (50 ng/ml) used as positive con-
trol (Figure 1F). These results reveal that Shh transactivates the
EGFR leading to its endocytosis.
In order to establish how much of the mitogenic effect of Shh
is mediated by the EGFR-dependent ERK1/2 pathway we tested
the effect of inhibiting its activating-kinase, MEK, with PD98059
(Alessi et al., 1995). PD98059 (100μM) almost completely inhib-
ited ERK1/2 activation (Figure 1G) and reduced the mitogenic
activity of nsps grown in the presence of Shh by 60% (Figure 1H).
Thus, the mitogenic effect of Shh upon NSCs seems to relay
substantially on transactivation of EGFR and the subsequent
engagement of the ERK1/2 pathway.
The mechanism of EGFR transactivation usually involves the
proteolytic release of ligands from the cell surface through the
activity of MMPs on ligand precursors (Izumi et al., 1998;
Prenzel et al., 1999). Ilomastat/(GM6001), currently used as a
general inhibitor of MMPs (Izumi et al., 1998; Prenzel et al.,
1999), reduced Shh-dependent proliferation of nsps by 55%
(Figure 1H), indicating that a similar MMP-dependent mecha-
nism is triggered by Shh. These results indicate that the mitogenic
signals conveyed by Shh acute stimulation requires transactiva-
tion of the EGFR through pathways involving metalloprotease
mediated release of EGFR ligands from the cell surface.
RADIAL GLIAL CELLS (RG) ARE THE MAIN TARGETS OF Shh
SIGNALING DURING LATE CORTICAL DEVELOPMENT
Shh has been implicated in the upregulation of EGFR expression
observed in NSC during late development, determining increased
responsiveness to EGF. RT-PCR analysis of neocortical tissue has
revealed that cyc treatment decreases the EGFR expression in vivo
(Palma and Ruiz i Altaba, 2004). However, it has not been demon-
strated that this modulation of EGFR expression translates to
effective changes at the protein level. To test this hypothesis we
compared the effect of Shh, EGF and bFGF on the expression of
EGFR. EGFR expression increased significantly in E18.5 neocorti-
cal explants treated for 48 h with Shh only in comparison to bFGF
or control samples, reaching even slightly higher levels when com-
pared to a positive control treatment with EGF (Figure 2A). We
next address the population of cells targeted by Shh in our model
system. One candidate are the RG cells that during late states
of embryonic development start to express GFAP (reviewed in
Imura et al., 2003; Ihrie and Alvarez-Buylla, 2008) and some of
them are EGF-responsive stem cells (Doetsch et al., 1999). We
analyzed the expression of GFAP by flow cytometry on neocor-
tical explants and found a significant decrement after 48 h of
Cyc treatment (Figure 2B), similar to the reduction in EGFR
expression. This observation suggests that Shh might be acting
on GFAP+ cells that express EGFR. In addition, immunostain-
ing of GFAP on 1 week plated single cell suspensions of nsps,
showed that GFAP expression is significantly affected, decreas-
ing by Cyc treatment and increasing by Shh only (Figure S1).
Of note, we were able to distinguish more cells with the charac-
teristic RG cell morphology after Shh treatment in comparison
to control growth factor deprived cultures. GFAP is indeed a
marker of NSCs both in the cortical region of late embryogene-
sis and in the subventricular zone (SVZ) of the adult, but it is also
expressed in many terminally differentiated astrocytes. Other cri-
teria is then needed to confirm that the RG-NSCs are the target of
Shh. RG cells are characterized by Sox2 expression, which marks
multipotent NSCs during different stages of mouse ontogeny
(Graham et al., 2003; Ellis et al., 2004). The glutamate transporter
(GLAST) is also a well-established marker of RG cells. Therefore,
we assessed the effect of Cyc on the expression of these two mark-
ers. Nsp cultures cells grown in the presence of EGF (10 ng/ml)
plus Cyc for 48 showed reduced levels of Sox2 by immunoblot
(Figure 2D). Nsps treated with Cyc also reduced the number
of cells expressing GLAST as evaluated by immunoblot and the
opposite was seen upon treatment with Shh (Figure 2E). All these
results strongly suggest that Shh acts on a specific progenitor pool:
the RG cells.
Taken together, our studies establish for the first time that the
stimulatory actions of EGF on NSC proliferation are mediated
partially by the activation of the Shh signal transduction pathway.
Shh ACUTE STIMULI MODULATE EGFR FUNCTION IN HeLa
CANCER CELLS
To assess whether Shh modulation of EGFR function is a more
general phenomena that might be extensive to cancerous cells,
we next performed similar experiments in HeLa cells. These
cells have been widely used to study EGFR function (Salazar
and González, 2002; Buvinic et al., 2007; Sigismund et al., 2008;
Norambuena et al., 2009) but to our knowledge have not been
studied as a Hedgehog signaling model system. Once ensured
that HeLa cells expressed the components of the Hedgehog path-
way through reverse transcriptase PCR (Figure 3A), we examined
the effect of Shh stimulation on HeLa cell proliferation. Cells
were deprived of any growth factor for 24 h and then incubated
in absence (control) or presence of recombinant Shh, Shh plus
its specific blocking antibody (5E-1), Shh plus the Gli inhibitor
Gant61, or EGF as positive control for another 24 h (Figure 3B).
Cell cycling, measured by BrdU incorporation after application of
a 1 h pulse, showed that Shh induced cell proliferation of HeLa
cells, which on the other hand showed a significant reduction
in the presence of the Shh blocking peptide, 5E1. Interestingly,
Shh treatment showed only a slight decrease in proliferation
with the canonical pathway inhibitor Gant61 (Figure 3C). These
results suggest that Shh might promote HeLa cell proliferation
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FIGURE 2 | Shh controls the pool of RG cells (GFAP+, Sox2+, GLAST+)
that express EGFR. (A) Western blot and densitometry analysis of EGFR
show higher levels of EGFR in Shh-treated explants in comparison to samples
treated with bFGF and positive control EGF. (B) Flow cytometry of cells
harvested from E18.5 cortical explants. Treatment for 48 h with Cyc (10μM)
provokes similar decreases in the pool of EGFR- and GFAP-expressing cells.
Histograms are representative of three independent experiments expressed
as the percentage of the mean ± and SEM (∗∗p < 0.01). (C) Western blot and
densitometry analysis of EGFR of E18.5 nsps cultures treated for 48 h as
indicated. (D) Immunoblots of Sox2 in NSCs. Treatment with Cyc for 48 h
showed a decreased in Sox2 mass respect to β-tubulin. (E) Histograms
showing the percentage of GLAST+ NSCs after 24 h treatment as indicated.
Data represent the results of three independent experiments expressed as
the percentage of the mean ± SEM (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
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FIGURE 3 | Sonic Hedgehog induces internalization of EGFR, activation
of ERK and proliferation of HeLa cells. (A) Expression of Hedgehog
signaling pathway components in HeLa cells. mRNA expression levels of
Gli1, Ptch1, and GAPDH were assessed by reverse transcription-polymerase
chain reaction (RT-PCR) in HeLa cells. (M = molecular mass; bp = base pair).
(B) Shh induces proliferation of HeLa cells in a non-canonical fashion. HeLa
cells were untreated (control) or treated with recombinant Shh or EGF as
positive control, for 30min before stimulation with Shh, Shh blocking
antibody 5E1 (5E1.5mg/ml) or Gli inhibitor Gant61 (Gant 10μM). Bar =
10μm. (C) Quantification of the percentage of BrdU+ cells stimulated with
EGF, Shh as indicated. A decrease in proliferation was observed in treatments
with 5E1 and proliferation was not fully inhibited with Gant treatment.
One-Way ANOVA p = 0.0002. (D) Shh treatment induces EGFR
internalization. HeLa cells stably expressing EGFR-GFP were incubated in the
absence (Control) or presence of Shh for 30min and visualized under
epifluorescence microscopy. Bar = 10μm. (E) Both EGF (positive control) and
Hedgehog agonist Pur acute treatments led to ERK1/2 signaling pathway
activation in these cells. (F) Pur does not induce ubiquitination of EGFR. Cells
were incubated in the absence (lane 1) or presence of either 50 ng/ml EGF
(lanes 2–5) or 10μM Pur (lanes 6–9) for the indicated time periods. EGFR was
then immunoprecipitated with mAb-HB8506, and its ubiquitin (UB) content
was assessed by immunoblot with anti-ubiquitin mAb P4D1. Total mass of
EGFR detected after incubating blots with polyclonal antibody EGFR984. In
contrast to EGF, Pur did not induce ubiquitination of EGFR.
from a non-canonical source, without direct mediation of the Gli
transcription factors.
One possibility is that Shh might be promoting cell prolif-
eration by EGFR transactivation. Although we could not detect
an increment of tyrosine-phosphorylation in EGFR assessed
by immunoblot we did observe internalization of the recep-
tor. HeLa cells, stably expressing EGFR-GFP, were depleted
and incubated with or without Shh and EGFR internaliza-
tion was examined under fluorescence microscopy after 30min.
Shh (3.3μg/ml) induced a redistribution of EGFR from the
cell surface to intracellular compartments indicative of EGFR
endocytosis (Figure 3D). Both Shh and Hedgehog agonist Pur
acute treatments led to ERK1/2 signaling pathway activation
in these cells (Figures 2, 3E). Acute Pur treatment showed no
evidence of EGFR degradation for up to 4 h (data not shown).
Actually, as opposed to 50 ng/ml EGF treatment, we did not
detect ubiquitination of the EGFR (Figure 3F). These results
show that Shh drives EGFR internalization and promotes a
transient mitogenic ERK1/2 signaling cascade activation. Shh
seems to mimic the effects reported for low concentrations of
EGF, which does not induce detectable ubiquitinylation and
leads to EGFR recycling rather than degradation, thus contrast-
ing with the effects of high ligand concentration (Sigismund
et al., 2005, 2008, 2013). Actually, a threshold for EGFR ubiq-
uitination has been recently reported in these cells (Sigismund
et al., 2013). Overall, these results suggest that EGFR is also a
downstream element in the Shh signaling pathway in HeLa cancer
cells.
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DISCUSSION
Acquisition and modulation of EGF responsiveness is critical in
the regulation of several aspects of NSC development, such as
self-renewal, differentiation and migration. Here we provide evi-
dence that one of the main functions of Shh during late stages of
brain embryogenesis is to promote and modulate EGF respon-
siveness of NSCs. We demonstrate that Shh has the capability
to transactivate the EGFR and as a consequence strengthens the
mitogenic intensity of the ERK1/2 signaling pathway triggered by
EGF. This effect can explain the collaborative function of Shh and
EGF exerted on the proliferation of late NSCs.
We identify RG (GFAP+, Sox2, and GLAST+) cells as the
main target population of Shh, in which Shh induced transacti-
vation, together with the reported EGFR expression (Dahmane
et al., 2001) can all contribute to increase the EGF responsive-
ness. Our results are in line with a recent report by Dave et al.,
which showed in vivo that Shh pathway activation in the condi-
tional Ptc1Lox/Lox; NestinCre mutant cortex is mitogenic for cells
that have a capacity to self-renew over an extended period of time.
Authors identified RG cells- Nestin+/GLAST+ as the direct tar-
gets in the developing neocortex by mid neurogenesis (E14.5).
Importantly, they showed reduction of Trb2 basal progenitor pos-
itive cells, suggesting that since RG cells can differentiate into
basal progenitors, an indirect effect on this cell population could
not be ruled out (Dave et al., 2011). In contrast Komada et al.
reported that in Shh-CKO and Smo-conditional mutant embryos,
the number of Tbr2-positive basal progenitor cells is significantly
decreased in the SVZ/VZ of the developing neocortex (Komada
et al., 2008). Furthermore, no significant differences could be
observed in the Pax6 positive-RG cells among E15.5 wild-type
and mutant mice. Clearly, this matter will require future inves-
tigation and we do not rule out that Shh signaling may be a
mechanism for the regulation of both the number of RG cells and
basal progenitors.
Our previous experiments in NSCs revealed synergism of the
Shh and EGF signaling pathways reflected by increments of pro-
liferative responses and induction of gene expression (Palma and
Ruiz i Altaba, 2004). This up-regulation of EGFR expression lev-
els induced by Shh indeed contributes to the collaborative action
of Shh and EGFR on NSCs. EGFR expression has been associated
with changes in progenitor cell behavior as a limiting factor for
both proliferation and differentiation with response choice regu-
lated in part by a concentration-dependent mechanism. Here we
show that the mitogenic mechanism employed by Shh stimulus
substantially depends on EGFR activity. Shh has been reported
to provoke acute transactivation of EGFR, leading to cell prolif-
eration in mouse embryonic stem cells (Heo et al., 2007). Our
present results are the first to show that Shh transactivates the
EGFR, leading to mitogenic ERK1/2 signaling in NSCs at late
embryonic stages. Treatment of E18.5 cortical nsps with Shh
for 15min increases the tyrosine phosphorylation of the EGFR,
a hallmark of its activation. Such Shh-induced EGFR phos-
phorylation was abrogated with an inhibitor of EGFR tyrosine
kinase activity, and had functional consequences, as it resulted
in activation of mitogenic ERK1/2 signaling. Recent observations
suggest that the ability of cells to divide in response to EGFR acti-
vation requires the expression of a high level of the receptor in
NSC (Lillien and Gulacsi, 2006). Because Shh can provoke an
acute as well as a sustained status of EGFR activation (Bigelow
et al., 2005; Heo et al., 2007), an initial event of EGFR transac-
tivation can play a role in increasing the levels of the EGFR as
well as in establishing regulatory loops acting on the proliferation
machinery. Thus, Shh and EGF signaling pathways can function-
ally interact at different levels and may even establish a long-term
regulatory loop depending on the cell context. How the syner-
gistic signaling system of Shh and EGFR are integrated in NCSs
and how does cooperativity between the pathways lead to selec-
tive activation of common response genes remains to be tested in
future studies.
Endocytic trafficking is a crucial element in the regulation
of EGFR function control (Goh and Sorkin, 2013; Pennock and
Wang, 2003). The intensity, location and duration of recep-
tor signaling can be modulated by the endocytic trafficking
machinery, which is tightly intertwined with the mechanisms
that control receptor signaling (Scita and Di Fiore, 2010; Goh
and Sorkin, 2013). Activated EGFR undergoes transphospho-
rylation and ubiquitylation and these modifications define its
endocytic trafficking/signaling behavior (Goh and Sorkin, 2013;
Sigismund et al., 2013). Recent studies have shown that low ligand
concentrations drive EGFR toward clathrin-dependent endocy-
tosis followed by recycling, whereas high ligand concentrations
promote EGFR internalization through a clathrin-independent
route directed to lysosomal degradation (Sigismund et al., 2008).
These alternatives have functional consequences in specifying
the responses (Sigismund et al., 2008) and involve a threshold-
controlled ubiquitylation system (Sigismund et al., 2013), which
finely tunes the balance between EGFR signaling and traffick-
ing. The ubiquitin-dependent down regulation route involves
ESCRT-mediated sorting into intraluminal vesicles of multi-
vesicular bodies that then fuse with lysosomes (Wegner et al.,
2011). Thus, activated EGFR can remain signaling-competent
for variable periods of time before degradation, determining dif-
ferent response outcomes (Sigismund et al., 2008; Rush et al.,
2012). Our results, both in NSC and in HeLa cells show that
Hedgehog pathway activation leads to EGFR internalization and
to transient activation of the MAPK/ERK signaling cascade
(Figure 1D, Figure S2), without detectable ubiquitination. This
mimics the effect induced on EGFR by low EGF concentrations,
which mainly leads to receptor recycling instead of degradation
(Sigismund et al., 2008). In contrast, high EGF doses stimu-
lation (50 ng/ml) induces EGFR ubiquitination and promotes
its sorting to the lysosomal degradation pathway (Figure 3F).
Besides mimicking EGFR stimulation by low EGF concentra-
tion, which by itself can constitute a strong mitogenic stimulus
(Sigismund et al., 2008), another possibility of Shh-mediated
regulation of EGFR function might occur through the reduc-
tion of PKA activity produced by activation of Smo via Gαi
(Huangfu and Anderson, 2006). A decreased PKA activity has
been shown to induce endocytosis and intracellular accumulation
of empty/inactive EGFR, as well as an increment in the half-life
of ligand-activated EGFR by delaying its sorting to the lysoso-
mal degradation route (Salazar and González, 2002; Norambuena
et al., 2010).
Our findings provide evidence that Shh, constitutes a mito-
genic stimulating system, activating the EGFR and itsMAPK/ERK
signaling cascade. This potentiates the mitogenic effects of low
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EGF concentrations. Taking into account the recently described
Shh constitutive autocrine modulation in NSCs (Bigelow et al.,
2005; Ruiz i Altaba et al., 2007; Martínez et al., 2013), our
results suggest that downstram activation of EGFR might pro-
vide the necessary strength to the intracellular pathways to mount
a mitogenic response in NSCs. This might eventually increase
the expression of EGFR, as previously reported for other EGFR
transactivating receptors (Buvinic et al., 2007).
We suggest that during late development, neural precursor cell
proliferation would be regulated by an interplay of mechanisms
involving different signaling pathways, which would control the
size of the progenitor pool. Additional approaches addressing the
relationship of Shh, EGFR and others signaling pathways will be
required order to obtain a better understanding of how, when and
where these pathways interact to control NSC behavior.
Although at the moment specific mechanisms of EGFR trans-
activation by Shh are not defined, we show the intermediary
action of MMPs in Shh-induced proliferation in NSCs. Our
results show that Shh elicits a mitogenic response through acti-
vation of GM6001-sensitive MMPs. Inhibition of MMP activity
attenuates the Shh-mediated cell proliferation indicating that
the release of soluble ligands by induction of GM6001-sensitive
MMPs after Shh stimulation could be responsible for cell prolif-
eration. Our findings complement those described recently in ES
cells by Heo et al. (2007). However, in NSCs, the identity ofMMPs
and their mechanism still remain to be defined.
Transactivation of the EGFR by agonist-activated GPCRs typ-
ically requires growth factor cleavage mediated by MMPs. It is
noteworthy that the transactivation of the EGFR, mediated by
members of the ADAM (a disintegrin and metalloproteinase)
family of zinc-dependent proteases, is relevant in the devel-
opment and progression of diverse types of human tumors.
Furthermore, there is evidence suggesting that brain tumors
resemble stem cell niches (Oliver andWechsler-Reya, 2004). Brain
tumors contain cancer stem cells, which are essential for both
development and recurrence of the tumors (Dahmane et al.,
2001; Vescovi et al., 2006). Together, these studies raise the pos-
sibility that the factors that regulate normal cell lineages from
neural precursors may serve similar functions in the devel-
opment of brain cancers from stem-like cancer cells (Ruiz i
Altaba et al., 2007). Integration of the Shh and EGFR path-
ways could be a critical step in cancer initiation and/or tumor
growth. Our data obtained in HeLa cells indeed suggest a con-
served essential role of Shh on the regulation of EGFR function,
which have therapeutic interest. The recognized importance of
the EGFR in tumorigenesis suggests the possibility that abnor-
mally increased Shh signaling contributes to carcinogenesis, thus
providing additional rational to Shh as a target for antitumor
therapies.
In conclusion, the present work gives further evidence of the
importance of Shh in the regulation of the homeostasis of the
EGF signaling pathways and proliferation, emphasizing cross-talk
processes. Our findings shed new insight into the complex signal
transduction pathways that mediate the actions of growth factors
in the developing brain.
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Figure S1 | Shh maintains a specific GFAP+ -RG cell pool. Nsps were
cultured for 48 h with EGF (10 ng/ml) and then EGF was removed and the
cells were cultured in the presence of only Shh (3μg/ml) or Cyc (10μM)
for 7 days. RG phenotype on treated nsps was assessed by
immunofluorescence staining for GFAP, counterstaining the cell nuclei
with DAPI Bar = 50μm. The percentage of cells expressing GFAP is
depicted in the corresponding histogram. Shh treatment increases 2-fold
the number of GFAP+ cells, whereas Cyc treatment shows the opposite
effect, decreasing by 50% the number of GFAP+ cells. Values are the
mean ± SEM of three experiments per conditions. (∗∗p < 0.01 vs. control).
Figure S2 | Shh treatment in HeLa cells induces activation of the
mitogenic ERK1/2 transduction pathway. HeLa cells treated with
3.3μg/ml Shh for the indicated time periods showed increased
phospho-ERK, detected by immunoblot, maximal at 30min.
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